Market Closed -
Japan Exchange
02:00:00 2024-06-03 am EDT
|
5-day change
|
1st Jan Change
|
391
JPY
|
-1.76%
|
|
-0.76%
|
-25.10%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9,122
|
24,246
|
15,031
|
14,666
|
7,390
|
8,950
|
Enterprise Value (EV)
1 |
8,452
|
20,058
|
11,160
|
11,388
|
4,310
|
6,243
|
P/E ratio
|
-7.2
x
|
28.5
x
|
-13.4
x
|
-26.2
x
|
-5.25
x
|
-7.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
12.1
x
|
7.56
x
|
13.3
x
|
7.27
x
|
5.33
x
|
5.51
x
|
EV / Revenue
|
11.2
x
|
6.25
x
|
9.85
x
|
5.65
x
|
3.11
x
|
3.84
x
|
EV / EBITDA
|
-7.46
x
|
20.3
x
|
-10.7
x
|
-22.2
x
|
-3.48
x
|
-5.77
x
|
EV / FCF
|
-10.6
x
|
17.9
x
|
-11.3
x
|
-7.85
x
|
-11.8
x
|
-4.84
x
|
FCF Yield
|
-9.45%
|
5.58%
|
-8.87%
|
-12.7%
|
-8.46%
|
-20.7%
|
Price to Book
|
10.3
x
|
6.42
x
|
3.93
x
|
3.4
x
|
2.03
x
|
2.31
x
|
Nbr of stocks (in thousands)
|
10,136
|
11,421
|
12,402
|
13,308
|
14,211
|
17,145
|
Reference price
2 |
900.0
|
2,123
|
1,212
|
1,102
|
520.0
|
522.0
|
Announcement Date
|
3/27/19
|
3/27/20
|
3/26/21
|
3/25/22
|
3/27/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
754
|
3,207
|
1,133
|
2,017
|
1,386
|
1,625
|
EBITDA
1 |
-1,133
|
987
|
-1,045
|
-512
|
-1,237
|
-1,082
|
EBIT
1 |
-1,145
|
978
|
-1,057
|
-531
|
-1,270
|
-1,117
|
Operating Margin
|
-151.86%
|
30.5%
|
-93.29%
|
-26.33%
|
-91.63%
|
-68.74%
|
Earnings before Tax (EBT)
1 |
-1,207
|
912
|
-1,103
|
-533
|
-1,323
|
-1,130
|
Net income
1 |
-1,210
|
828
|
-1,111
|
-534
|
-1,349
|
-1,152
|
Net margin
|
-160.48%
|
25.82%
|
-98.06%
|
-26.47%
|
-97.33%
|
-70.89%
|
EPS
2 |
-125.0
|
74.51
|
-90.33
|
-42.06
|
-99.06
|
-68.57
|
Free Cash Flow
1 |
-798.5
|
1,120
|
-990
|
-1,451
|
-364.5
|
-1,290
|
FCF margin
|
-105.9%
|
34.93%
|
-87.38%
|
-71.96%
|
-26.3%
|
-79.36%
|
FCF Conversion (EBITDA)
|
-
|
113.5%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
135.3%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/19
|
3/27/20
|
3/26/21
|
3/25/22
|
3/27/23
|
3/27/24
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2024 Q1
|
---|
Net sales
1 |
579
|
430
|
554
|
839
|
256
|
226
|
500
|
211
|
180
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-375
|
-777
|
1
|
-312
|
-441
|
-505
|
-863
|
-338
|
-416
|
Operating Margin
|
-64.77%
|
-180.7%
|
0.18%
|
-37.19%
|
-172.27%
|
-223.45%
|
-172.6%
|
-160.19%
|
-231.11%
|
Earnings before Tax (EBT)
1 |
-396
|
-780
|
-10
|
-349
|
-429
|
-513
|
-869
|
-338
|
-397
|
Net income
1 |
-397
|
-776
|
-15
|
-359
|
-436
|
-519
|
-885
|
-345
|
-398
|
Net margin
|
-68.57%
|
-180.47%
|
-2.71%
|
-42.79%
|
-170.31%
|
-229.65%
|
-177%
|
-163.51%
|
-221.11%
|
EPS
2 |
-32.60
|
-62.50
|
-1.120
|
-26.53
|
-32.03
|
-32.78
|
-53.81
|
-19.93
|
-23.27
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/7/20
|
8/6/21
|
5/10/22
|
8/5/22
|
11/7/22
|
5/10/23
|
8/7/23
|
11/7/23
|
5/10/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
670
|
4,188
|
3,871
|
3,278
|
3,080
|
2,707
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-799
|
1,120
|
-990
|
-1,451
|
-365
|
-1,290
|
ROE (net income / shareholders' equity)
|
-107%
|
34.9%
|
-28.9%
|
-13.1%
|
-33.9%
|
-30.7%
|
ROA (Net income/ Total Assets)
|
-36.1%
|
17.1%
|
-12.9%
|
-6.46%
|
-16.4%
|
-16.2%
|
Assets
1 |
3,348
|
4,840
|
8,586
|
8,260
|
8,241
|
7,108
|
Book Value Per Share
2 |
87.50
|
331.0
|
308.0
|
324.0
|
256.0
|
226.0
|
Cash Flow per Share
2 |
134.0
|
422.0
|
347.0
|
287.0
|
238.0
|
169.0
|
Capex
1 |
58
|
41
|
64
|
41
|
126
|
11
|
Capex / Sales
|
7.69%
|
1.28%
|
5.65%
|
2.03%
|
9.09%
|
0.68%
|
Announcement Date
|
3/27/19
|
3/27/20
|
3/26/21
|
3/25/22
|
3/27/23
|
3/27/24
|
|
1st Jan change
|
Capi.
|
---|
| -25.10% | 45.69M | | +43.36% | 54.63B | | -5.31% | 39.92B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B | | -11.83% | 10.74B |
Other Biotechnology & Medical Research
|